Inhibition of Helicobacter pylori infection in humans by Lactobacillus reuteri ATCC 55730 and effect on eradication therapy: A pilot study

Helicobacter

Volumn 13, Issue 2, 2008, Pages 127-134

  Francavilla, Ruggiero ^a,c,e   Lionetti, Elena ^a   Castellaneta, Stefania Paola ^b   Magistà, Anna Maria ^a   Maurogiovanni, Giovanni ^c   Bucci, Nunzia ^a   De Canio, Angela ^a   Indrio, Flavia ^a   Cavallo, Luciano ^a,e   Ierardi, Enzo ^d   Miniello, Vito Leonardo ^a  

^a UNIVERSITY OF BARI   (Italy)

^b Ospedale San Paolo   (Italy)

^c POLICLINICO   (Italy)

^d UNIVERSITY OF FOGGIA   (Italy)

^e Centro Interdipartimentale Gastroenterologia Ed Epatologia Età Evolutiva   (Italy)

Author keywords

Bacterial load; Helicobacter pylori; Lactobacillus reuteri; Probiotics

Indexed keywords

AMOXICILLIN; BACTERIAL ANTIGEN; CLARITHROMYCIN; PLACEBO; PROBIOTIC AGENT; RABEPRAZOLE; TINIDAZOLE;

ADULT; AGED; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DYSPEPSIA; ERADICATION THERAPY; FECES ANALYSIS; FEMALE; GASTROSCOPY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; LACTOBACILLUS REUTERI; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SINGLE BLIND PROCEDURE; TREATMENT DURATION; UREA BREATH TEST;

ANTI-BACTERIAL AGENTS; ANTIGENS, BACTERIAL; DOUBLE-BLIND METHOD; FECES; GASTRITIS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; LACTOBACILLUS REUTERI; PILOT PROJECTS; PROBIOTICS; UREA;

BACTERIA (MICROORGANISMS); HELICOBACTER PYLORI; LACTOBACILLUS REUTERI;

EID: 40449120392     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/j.1523-5378.2008.00593.x     Document Type: Article

References (46)

1. Palli D, Menegatti M, Masala G, Ricci C, Saieva C, Holton J, Gatta L, Miglioli M, Vaira D. Helicobacter pylori infection, anti-cagA antibodies and peptic ulcer: a case-control study in Italy. Aliment Pharmacol Ther 2002 16: 1015 8.
2. Bayerdorffer E, Morgner A. Gastric marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type: management of the disease. Dig Liver Dis 2000 32: 192 4.
3. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N, Schlemper RJ. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001 345: 784 9.
4. Malfertheiner P, Megraud F, O'morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007 56: 772 81.
5. Nord CE, Heimdal A, Kager L. Antimicrobial induced alterations of the human oropharyngeal and intestinal microflora. Scand J Infect Dis 1986 49: 64 72.
6. Adamsson I, Nord CE, Lundquist P, Sjöstedt S, Edlund C. Comparative effectsof omeprazole, amoxycillin, plus metronidazole versus omeprazole, clarithromycin plus metronidazole on the oral, gastric and intestinal microflora in Helicobacter pylori-infected patients. J Antimicrob Chemother 1999 44: 629 40.
7. 13C-urea breath test. Gastroenterol Clin North Am 2000 29: 885 93.
8. 13C-urea breath test to assess Helicobacter pylori bacterial load. Helicobacter 2005 10: 615 9.
9. 13C-urea breath test: reproducibility and association with the severity of Helicobacter pylori-associated antral gastritis. J Gastroenterol Hepatol 2005 20: 270 4.
10. Weizman Z, Asli G, Alsheikh A. Effect of a probiotic infant formula on infections in child care centers: comparison of two probiotic agents. Pediatrics 2005 115: 5 9.
11. Shornikova A, Casas IA, Isolauri E, Mykkanen H, Vesikari T. Lactobacillus reuteri as a therapeutic agent in acute diarrhea in young children. J Pediatr Gastroenterol Nutr 1997 24: 399 404.
12. Valeur N, Engel P, Carbajal N, Connolly E, Ladefoged K. Colonization and immunomodulation by Lactobacillus reuteri ATCC 55730 in the human gastrointestinal tract. Appl Envirol Microbiol 2004 70: 1176 81.
13. Mukai T, Asasaka T, Sato E, Mori K, Matsumoto M, Ohori H. Inhibition of binding of Helicobacter pylori to the glycolipid receptors by probiotic Lactobacillus reuteri. FEMS Immunol Med Microbiol 2002 32: 105 10.
14. Lionetti E, Miniello VL, Castellaneta SP, Magista AM, de Canio A, Maurogiovanni G, Ierardi E, Cavallo L, Francavilla R. Lactobacillus reuteri therapy to reduce side-effects during anti-Helicobacter pylori treatment in children: a randomized placebo controlled trial. Aliment Pharmacol Ther 2006 24: 1461 8.
15. Logan RP, Polson RJ, Misiewicz JJ, Rao G, Karim NQ, Newell D, Johnson P, Wadsworth J, Walker MM, Baron JH. Simplified single sample 13carbon urea breath test for Helicobacter pylori. Comparison with histology, culture, and ELISA serology. Gut 1991 32: 1461 4.
16. Ierardi E, Margiotta M, Monno R, De Francesco V, Minenna MF, Burattini O, Faleo D, Panella C, Francavilla A, Cuomo R. A new semiquantitative method of quantifying Helicobacter pylori in antigen stools. J Clin Gastroenterol 2002 35: 375 8.
17. Dryer RL, Lata GF. Experimental Biochemistry. Oxford, UK: Oxford University Press, 1989 376 8.
18. Svedlund J, Sjodin I, Dotevall G. GSRS: a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci 1988 33: 129 34.
19. Zullo A, Vaira D, Vakil N, et al. High eradication rates of Helicobacter pylori with a new sequential treatment. Aliment Pharmacol Ther 2003 17: 719 26.
20. Cats A, Kuipers EJ, Bosschaert MA, Pot RG, Vandenbroucke-Grauls CM, Kusters JG. Effect of frequent consumption of a Lactobacillus casei-containing milk drink in Helicobacter pylori-colonized subjects. Aliment Pharmacol Ther 2003 17: 429 35.
21. 13C-urea breath test as a predictor of intragastric bacterial load and severity of Helicobacter pylori gastritis. Scand J Clin Lab Invest 1998 58: 19 27.
22. Sekizuka E, Grisham MB, Li MA, Deitch EA, Granger DN. Inflammation-induced intestinal hyperemia in the rat: role neutrophils. Gastroenterology 1988 95: 1528 34.
23. Sasayama Y, Kawano S, Tsuji S, Fusamoto H, Kamada T, Fukui H, Yoneda S, Okishio T. Relationship between interleukin-8 levels and myeloperoxidase activity in human gastric mucosa. J Gastroenterol Hepatol 1997 12: 104 8.
24. Khulusi S, Mendall MA, Patel P, Levy J, Badve S, Northfield TC. Helicobacter pylori infection density and gastric inflammation in duodenal ulcer and non-ulcer subjects. Gut 1995 37: 319 24.
25. Alam K, Schubert TT, Bologna SD, Ma CK. Increased density of Helicobacter pylori on antral biopsy is associated with severity of acute and chronic inflammation and likelihood of duodenal ulceration. Am J Gastroenterol 1992 87: 424 8.
26. Sakamoto I, Igarashi M, Kimura K, Takagi A, Miwa T, Koga Y. Suppressive effect of Lactobacillus gasseri OLL 2716 (LG21) on Helicobacter pylori infection in humans. J Antimicrob Chemother 2001 47: 709 10.
27. Michetti P, Dorta G, Wiesel PH, et al. Effect of whey-based culture supernatant of Lactobacillus acidophilus (johnsonii) La1 on Helicobacter pylori infection in humans. Digestion 1999 60: 203 9.
28. Cruchet S, Obregon MC, Salazar G, Diaz E, Gotteland M. Effect of the ingestion of a dietary product containing Lactobacillus johnsonii La1 on Helicobacter pylori colonization in children. Nutrition 2003 19: 716 21.
29. Myllyluoma E, Veijola L, Ahlroos T, Tynkkynen S, Kankuri E, Vapaatalo H, Rautelin H, Korpela R. Probiotic supplementation improves tolerance to Helicobacter pylori eradication therapy - a placebo-controlled, double-blind randomized pilot study. Aliment Pharmacol Ther 2005 21: 1263 72.
30. Gotteland M, Brunser O, Cruchet S. Systematic review: are probiotics useful in controlling gastric colonization by Helicobacter pylori? Aliment Pharmacol Ther 2006 15: 1077 86.
31. Wendakoon CN, Thomson ABR, Ozimek L. Lack of therapeutic effect of a specially designed yogurt for the eradication of Helicobacter pylori. Digestion 2002 65: 16 20.
32. Gotteland M, Cruchet S. Suppressive effect of frequent ingestion of Lactobacillus johnsonii La1 on Helicobacter pylori colonization in asymptomatic volunteers. J Antimicrob Chemother 2003 51: 1317 9.
33. Wang KY, Li SN, Liu CS, Perng DS, Su YC, Wu DC, Jan CM, Lai CH, Wang TN, Wang WM. Effects of ingesting Lactobacillus- and Bifidobacterium-containing yogurt in subjects with colonized Helicobacter pylori. Am J Clin Nutr 2004 80: 737 41.
34. Shimizu T, Haruna H, Hisada K, Yamashiro Y. Effects of Lactobacillus gasseri OLL 2716 (LG21) on Helicobacter pylori infection in children. J Antimicrobial Chemother 2002 50: 617 8.
35. Pantoflickova D, Corthésy-Theulaz I, Dorta G, Stolte M, Isler P, Rochat F, Enslen M, Blum AL. Favourable effect of regular in take of fermented milk containing Lactobacillus johnsonii on Helicobacter pylori associated gastritis. Aliment Pharmacol Ther 2003 18: 805 13.
36. Gotteland M, Poliak L, Cruchet S, Brunser O. Effect of regular ingestion of Saccharomyces boulardii plus inulin or Lactobacillus acidophilus in children colonised by Helicobacter pylori. Acta Paediatr 2005 94: 1747 51.
37. Shornikova AV, Casas IA, Mykkänen H, Salo E, Vesikari T. Bacteriotherapy with Lactobacillus reuteri in rotavirus gastroenteritis. Pediatr Infect Dis J 1997 16: 1103 7.
38. Wolf BW, Wheeler KB, Ataya DG, Garleb KA. Safety and tolerance of Lactobacillus reuteri supplementation to a population infected with the human immunodeficiency virus. Food Chem Toxicol 1998 36: 1085 94.
39. Conway PL, Gorbach SL, Goldin BR. Survival of lactic acid bacteria in the human stomach and adhesion to intestinal cells. J Dairy Sci 1987 70: 1 12.
40. Johnson C, Dicksved J, Jonsson H, Roos S. Anti Helicobacter pylori activity among lactic acid bacteria isolated from gastric biopsies and strains of Lactobacillus reuteri. (Abstract) Helicobacter 2003 8: 473.
41. Lewis SJ, Freedman AR. Rewiev article: the use of biotherapeutic agents in the prevention and treatment of gastrointestinal disease. Aliment Pharmacol Ther 1998 12: 807 22.
42. Jack RW, Tagg JR, Ray B. Bacteriocins of gram-positive bacteria. Microbiol Rev 1995 59: 171 200.
43. Marteau P, Rambaud JC. Potential of using lactic acid bacteria for therapy and immunomodulation in man. FEMS Microbiol Rev 1993 12: 207 20.
44. Brandt LJ, Bjorkman D, Fennerty MB, Locke GR, Olden K, Peterson W, Quigley E, Schoenfeld P, Schuster M, Talley N. Systematic review on the management of irritable bowel syndrome in North America. Am J Gastroenterol 2002 97: S7 26.
45. Young P, Cash BD. Probiotic use in irritable bowel syndrome. Curr Gastroenterol Report 2006 8: 321 6.
46. Tindberg Y, Blennow M, Glanstrom M. Clinical symptoms and social factors in a cohort of children spontaneously clearing Helicobacter pylori infection. Acta Pediatrica 1999 88: 631 5.